Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2022

View Archived Issues

RBD-PB6 RNA aptamer blocks SARS-CoV-2 entry into host cells

Antibodies against SIRPA and SIRPB1 promote antitumoral effect in preclinical study

Icahn School of Medicine at Mount Sinai patents DYRK1A inhibitors

Medshine Discovery divulges new GTPase KRAS G12C mutant inhibitors

X4 Pharmaceuticals presents new CXCR4 antagonists

Gilead Sciences synthesizes new HIV antivirals

Sage Therapeutics discloses new GABA-A receptor modulators

Everest Medicines licenses global rights to EDDC's 3CL protease inhibitors to treat COVID-19

Researchers develop a novel murine model of Cockayne syndrome

HGF mimetic CM-1021 stimulates liver growth in mice

[225Ac]OTSA-101 confers complete remission in preclinical model of synovial sarcoma

Study brings clarity on how MS starts, although not yet why

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...